What antihypertensive regimen is recommended for a hypertensive patient with impaired renal function?

Antihypertensive Management in Patients with Impaired Renal Function

Start with a renin-angiotensin system inhibitor (ACE inhibitor or ARB) as first-line therapy, titrated to the highest tolerated dose, targeting blood pressure <130/80 mmHg in most patients with chronic kidney disease. 1

First-Line Therapy Selection

RAS Inhibitors as Primary Agents

• ACE inhibitors or ARBs are the cornerstone of treatment for hypertensive patients with CKD, particularly when albuminuria is present 1
• For patients with severely increased albuminuria (A3) without diabetes, RAS inhibitors are strongly recommended (Grade 1B) 1
• For patients with moderately-to-severely increased albuminuria (A2-A3) with diabetes, RAS inhibitors are strongly recommended (Grade 1B) 1
• Even in patients with no albuminuria, RAS inhibitors remain a reasonable first choice regardless of diabetes status 1

Dosing Strategy

• Titrate to the highest approved dose that is tolerated—the proven renal and cardiovascular benefits were achieved in trials using maximal doses, not submaximal ones 1
• This aggressive dosing approach is critical for achieving nephroprotection beyond simple blood pressure reduction 1

Monitoring Requirements

Initial Monitoring Window

• Check blood pressure, serum creatinine, and potassium within 2-4 weeks after initiating or increasing RAS inhibitor dose 1
• The monitoring interval depends on baseline GFR and potassium levels—patients with lower GFR or higher potassium require closer surveillance 1

Acceptable Changes in Renal Function

• Continue RAS inhibitor therapy unless creatinine rises >30% within 4 weeks of initiation or dose increase 1
• A creatinine rise ≤30% represents acceptable hemodynamic adjustment and does not require dose reduction 1

Managing Hyperkalemia

• Do not automatically discontinue RAS inhibitors for hyperkalemia—first attempt medical management to reduce potassium levels 1
• Hyperkalemia can often be controlled with dietary potassium restriction, diuretics, or potassium binders while maintaining nephroprotective RAS inhibition 1

Blood Pressure Targets

• Target office BP <130/80 mmHg in most patients with CKD 2
• Avoid targeting BP <120/70 mmHg as this may increase risks without additional benefit 2
• These targets balance cardiovascular protection against risks of hypotension and acute kidney injury 2

Second-Line and Combination Therapy

Adding Additional Agents

• Dihydropyridine calcium channel blockers (CCBs) are rational second-line agents when combined with RAS inhibitors 1, 3
• Loop diuretics become necessary as renal function deteriorates (thiazides lose efficacy when GFR declines significantly) 4
• Use low diuretic doses initially to prevent hypovolemia, hyponatremia, and hypokalemia, which can worsen renal blood flow 4

Resistant Hypertension Management

• For eGFR ≥30 mL/min/1.73 m²: consider adding spironolactone (mineralocorticoid receptor antagonist) 2
• For eGFR <30 mL/min/1.73 m²: consider adding chlorthalidone instead 2
• Monitor closely for hyperkalemia and reversible GFR decline when using mineralocorticoid receptor antagonists, especially with low eGFR 1

Novel Agents

• SGLT2 inhibitors are recommended for patients with CKD and eGFR ≥20 mL/min/1.73 m² 2
• Finerenone (nonsteroidal mineralocorticoid receptor antagonist) is indicated for patients with CKD, type 2 diabetes, albuminuria, eGFR ≥25 mL/min/1.73 m², and potassium <5.0 mmol/L 2

Critical Contraindications

Combination Therapy to Avoid

• Never combine ACE inhibitor + ARB + direct renin inhibitor in any patient with CKD, regardless of diabetes status (Grade 1B) 1
• Dual or triple RAS blockade increases risks of hyperkalemia, hypotension, and acute kidney injury without additional benefit 1

When to Reduce or Discontinue RAS Inhibitors

Specific Scenarios Requiring Dose Adjustment

• Symptomatic hypotension despite volume optimization 1
• Uncontrolled hyperkalemia despite medical treatment (after attempting potassium-lowering strategies) 1
• Advanced kidney failure (eGFR <15 mL/min/1.73 m²) to reduce uremic symptoms while treating kidney failure 1
• Creatinine rise >30% within 4 weeks of initiation or dose increase 1

Special Populations

Kidney Transplant Recipients

• Use dihydropyridine CCB or ARB as first-line therapy in kidney transplant recipients with hypertension (Grade 1C) 1
• Target BP <130/80 mmHg using standardized office measurements 1

Common Pitfalls to Avoid

• Do not prematurely discontinue RAS inhibitors for mild creatinine elevations (<30% increase) or manageable hyperkalemia 1
• Do not use submaximal doses of RAS inhibitors—nephroprotection requires adequate dosing 1
• Do not combine multiple RAS blocking agents—this increases harm without benefit 1
• Do not continue thiazide diuretics when GFR is significantly reduced—switch to loop diuretics 4
• Do not ignore volume status—many patients with advanced CKD have volume-dependent hypertension requiring diuretic optimization 5